MetaVia Inc. Share Price & Technical Analysis
MTVA · $3.85 (+34.15%)
Healthcare / Biotechnology
$3.85
+34.15%
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as c…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
153% return in May, -6% avg return in past 3 year May month.
36% return in 2026, -50% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -72% | -42% | -20% | 17% | 153% | – | – | – | – | – | – | – | 36% |
| 25 | -11% | -16% | 5% | -53% | -14% | -4% | -9% | 6% | 51% | 5% | -21% | -1% | -62% |
| 24 | -12% | 46% | -27% | -21% | 11% | 22% | -18% | -11% | -15% | -18% | 0% | -13% | -57% |
| 23 | 13% | -19% | 12% | -15% | -16% | -21% | 17% | -13% | 8% | -5% | 6% | 0% | -32% |
| 22 | -14% | -23% | 16% | -29% | -32% | 7% | -11% | -24% | 48% | -42% | -81% | -51% | -237% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Exhausted
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.33M
P/E ratio
—
52W high
$19.03
52W low
$0.97
Volume
4,03,38,057
Beta
0.58
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MetaVia Inc. share price today?
- MetaVia Inc. (MTVA) last traded around $3.85 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MTVA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MTVA. Download the app for real-time alerts.
- How can I analyze MetaVia Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.